Frankfurt - Delayed Quote EUR
Insulet Corporation (GOV.F)
276.70
+47.10
+(20.51%)
At close: May 9 at 9:55:01 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 23 | 23 |
| Avg. Estimate | 610.7M | 642.67M | 2.51B | 2.94B |
| Low Estimate | 576.2M | 627.7M | 2.43B | 2.81B |
| High Estimate | 618.5M | 652.4M | 2.55B | 3.04B |
| Year Ago Sales | 488.5M | 543.9M | 2.07B | 2.51B |
| Sales Growth (year/est) | 25.02% | 18.16% | 21.02% | 17.36% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GOV.F | -- | -- | -- | -- |
| S&P 500 | 13.21% | 3.09% | 8.02% | 13.76% |
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 5/9/2025 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 4/30/2025 |
| Downgrade | Wolfe Research: Outperform to Peer Perform | 4/29/2025 |
| Initiated | RBC Capital: Outperform | 3/6/2025 |
| Maintains | Citigroup: Buy to Buy | 2/21/2025 |
| Reiterates | Raymond James: Outperform to Outperform | 2/21/2025 |